• Mednow (MNOW) has released its financial results for the period ending January 31, 2022
  • Q2 revenue increased by over 230 per cent quarter-over-quarter and more than 1,400 per cent year-over-year
  • Karim Nassar, CEO of Mednow sat down with Dave Jackson to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at C$0.81 per share

Mednow (MNOW) has released its financial results for the period ending January 31st, 2022. 

Q2 revenue increased by over 230 per cent quarter-over-quarter and more than 1,400 per cent year-over-year.

Karim Nassar, CEO and Co-Founder of Mednow Inc. sat down with Dave Jackson to discuss the results.

“I am so fortunate to work with a gifted team of Mednow employees who have tirelessly committed their time and skills to build out Mednow’s vision of leading the digital health evolution, to redefine pharmacy’s role in holistic care.

Over the last quarter, we have continued to accelerate revenue, while enhancing our technology applications, growing our tuck-in acquisitions, and increasing our uniquely differentiated product offerings. We are thrilled to be able to service customers coast-to-coast by summer 2022, and we will now embark on a significant national marketing campaign.”

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at C$0.81 per share. 

More From The Market Online
stock market down

@ the Bell: TSX loses hold of gains

Despite an early jump in copper prices, Canada’s main stock index lost ground on Monday as resource stocks fell.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.

This gambling tech stock might be the safest bet you’ll make this year 

With headquarters out of Vancouver, Jackpot Digital develops dealerless electronic table games suited for today’s digital age.  
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.